Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG.
The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center Department of Vascular Surgery
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Sentara Norfolk General Hospital Vascular & Transplant Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with ESRD who are not, or who are no longer candidates for creation of an autologous AV fistula and therefore need placement of an AV graft in the upper extremity to start or maintain hemodialysis therapy
- Age 18 to 80 years old, inclusive
- Suitable anatomy for implantation of straight forearm grafts or curved upper arm grafts (arterial anastomosis to radial or brachial artery, venous anastomosis to either brachial cephalic or very central basilica vein)
- Hemoglobin ≥8 g/dL and platelet count ≥100,000 cells/mm3 prior to Day 1
- Other hematological and biochemical parameters within a range consistent with ESRD and acceptable for the administration of general anesthesia prior to Day 1
- Adequate liver function, defined as serum bilirubin ≤1.5 mg/dL; GGT, AST, ALT, and alkaline phosphatase ≤2x upper limit of normal or international normalized ratio (INR) ≤1.5 prior to Day 1.
- Able to communicate meaningfully with investigative staff, competent to give written informed consent, and able to comply with entire study procedures
- Able and willing to give informed consent
- Life expectancy of at least 1 year
Exclusion Criteria:
- History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within 6 months of study entry (Day 1), ventricular tachyarrhythmias requiring continuing treatment, or unstable angina
- Uncontrolled or poorly controlled diabetes; hospitalization for poor glucose control within the previous 6 months is an absolute exclusion criterion
- History or evidence of severe peripheral vascular disease in the upper limbs
- Known or suspected central vein obstruction on the side of planned graft implantation
- Stroke within 6 months of study entry (Day 1)
- Candidate for renal transplantation
- Treatment with any investigational drug or device within 60 days prior to study entry (Day 1)
- Treatment with vitamin K-antagonists, factor Xa inhibitors, or direct thrombin inhibitors within the month prior to study entry (Day 1)
- Female patients who are pregnant, intending to become pregnant, nursing or intending to nurse during the study
- Female patients of child bearing potential (not surgically sterile or at least 2 years post menopause) who do not use a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly), eg, implants, injectables, combined oral contraceptives in combination with a barrier method, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
- History of cancer with active disease or treatment within the previous year
- Immunodeficiency including AIDS / HIV
- Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous intravascular thrombotic events (thromboses of previous dialysis accesses do not count)
- Bleeding diathesis
- Active clinically significant autoimmune disease
- History of heparin-induced thrombocytopenia
- Previous PTFE graft in the operative limb unless the HAVG can be placed more proximally than the previous failed graft
- More than 1 failed PTFE graft in the operative limb
- Active local or systemic infection (WBC > 15,000 cells/mm3)
- Patients receiving a forearm graft with which crosses the elbow
- Patients receiving an upper arm graft with arterial anastomosis to the axillary artery or venous anastomosis to the axillary vein unless low in the axilla and accessible for ultrasound monitoring and compression
- Patients receiving a lower extremity AV access
- Known serious allergy to aspirin
- Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the HAVG
- Previous enrollment in this study
- Employees of the sponsor or patients who are employees or relatives of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: HAVG
Surgical placement of HAVG
|
HAVG is implanted into patients' arm.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HAVG graft assessment
Time Frame: From baseline to week 26 after HAVG implantation.
|
The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be assessed by Doppler ultrasound and tabulated.
|
From baseline to week 26 after HAVG implantation.
|
|
HAVG patency rate
Time Frame: at Week 26 after HAVG implantation
|
Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG by Doppler ultrasound.
|
at Week 26 after HAVG implantation
|
|
Adverse Events
Time Frame: From baseline to week 26 after HAVG implantation.
|
Frequency and severity of AEs of each patient will be documented.
|
From baseline to week 26 after HAVG implantation.
|
|
HAVG graft interventions
Time Frame: From baseline to week 26 after HAVG implantation.
|
Graft interventions of each patient will be documented.
|
From baseline to week 26 after HAVG implantation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in Panel Reactive Antibody
Time Frame: From baseline to day 29, weeks 12 and 26 after HAVG implantation.
|
Assess changes in the Panel Reactive Antibody response over the 6 months after graft implantation.
|
From baseline to day 29, weeks 12 and 26 after HAVG implantation.
|
|
Development of IgG antibodies
Time Frame: From baseline to day 29, weeks 12 and 26 after HAVG implantation.
|
Determine whether IgG antibodies to the extracellular matrix material are formed in response to implantation of the HAVG.
|
From baseline to day 29, weeks 12 and 26 after HAVG implantation.
|
|
Graft interventions
Time Frame: At each visit, i.e. day 1, day 4-7, day 15, day 29, day 57, week 12, week 16, 20, 26 after HAVG implantation.
|
Determine the rates of interventions needed to maintain / restore patency in the graft.
|
At each visit, i.e. day 1, day 4-7, day 15, day 29, day 57, week 12, week 16, 20, 26 after HAVG implantation.
|
|
HAVG patency rates
Time Frame: at 12, 18, 24 months after HAVG implantation.
|
Patency rates (primary, primary assisted, and secondary)
|
at 12, 18, 24 months after HAVG implantation.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Lynda H Szczech, MD, MSCE, Humacyte, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CLN-PRO-V003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.